Antineoplastic agents, 301. An investigation of the amaryllidaceae genus hymenocallis

George Pettit, George R. Pettit, Grazyna Groszek, Ralph A. Backhaus, Dennis L. Doubek, Roland J. Barr, Alan W. Meerow

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


Seven species (and one cultivated variety) of Hymenocallis (Amaryllidaceae) and the related Pancratium maritima, representing a broad geographical selection, were investigated as sources of pancratistatin [1] now undergoing preclinical development as an anticancer agent. Pancratistatin [1] was found to be a constituent of H. speciosa (Singapore), H. variegated (Singapore), H. pedalis (Seychelles), H. expansa (Bermuda), H. sonoranensis (Mexico), and P. maritimum (Israel). Only two species of Hymenocallis failed to yield one or more of the related cell-growth inhibitory isocarbostyrils such as narciclasine [3a], 7-deoxynarciclasine [3b], and 7-deoxy-trans-dihydronarciclasine [2].

Original languageEnglish (US)
Pages (from-to)756-759
Number of pages4
JournalJournal of Natural Products
Issue number5
StatePublished - May 1995

ASJC Scopus subject areas

  • Analytical Chemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine
  • Organic Chemistry


Dive into the research topics of 'Antineoplastic agents, 301. An investigation of the amaryllidaceae genus hymenocallis'. Together they form a unique fingerprint.

Cite this